Korea’s KOSDAQ biotech sector is lighting up trading screens in mid-2026, with a wave of small-cap biotech IPOs and share price surges drawing retail and institutional attention alike. But beneath the excitement lies a more complicated story — one of liquidity rotations, questionable valuations, and the age-old question of whether Korean small-caps are genuinely undervalued or simply catching a speculative tailwind. We brought together three of our regular analysts to debate what’s really driving the move, and whether investors should be chasing it.
Let’s be clear about what’s actually happening here. The KOSPI has broken through 8,000 — something that would have seemed unthinkable during the “Boxpi” years of the 2010s — and that macro tailwind is lifting everything, including assets that have no business being lifted. The AI-driven memory cycle, anchored by SK Hynix and Samsung, has been the engine of Korea’s broader market re-rating. But when the tide rises this aggressively, it doesn’t just lift the well-built ships. It lifts the debris too. That’s what we’re seeing in KOSDAQ biotech.
The structural backdrop matters enormously here. The recent regulatory relaxation allowing foreign individual investors to access Korean equities directly through platforms like Interactive Brokers has fundamentally changed the supply-demand equation for Korean equities. Global retail money is flowing in, and it’s moving predictably — first to large-cap names they understand, then to smaller, higher-beta stories that promise asymmetric upside. Biotech checks that box perfectly: narrative-rich, hard to value, and easy to pump on headline news. We’ve seen this movie before.
What worries me most is that the conditions driving this surge are fragile. U.S. Treasury yields remain elevated, and every time Fed rate-cut expectations get pushed back — as they were when recent strong U.S. employment data hit the wires — we’ve seen violent foreign selling in Korea, with outflows exceeding 6 trillion won in single sessions. KOSDAQ biotech, with its almost entirely domestic retail investor base and thin liquidity, is acutely vulnerable to that kind of reversal. These stocks are surging because the macro environment is temporarily permissive. When it stops being permissive, the hangover will be severe.
I’ll grant the Bear one thing: most of what’s moving in KOSDAQ biotech right now is noise. But to dismiss the entire sector as speculative froth is to miss some genuinely interesting fundamental setups. The key — as always — is separating the signal from the noise, and right now the noise is very loud.
Take the IPO pipeline specifically. Several upcoming biotech listings are showing characteristics that legitimately justify institutional interest. One ADC-focused platform company entering the market is operating in a space — antibody-drug conjugates — where global Big Pharma has been aggressively acquiring and licensing since 2011. When companies like Pfizer, Roche, and Seagen have spent billions validating a technology platform, a domestic Korean firm with credible linker and payload technology deserves a serious look, not a reflexive dismissal. Similarly, a biosimilars developer with a market cap in the 380 billion won range, a free-float of only around 16%, and strong institutional lock-up participation is a structurally interesting situation on listing day — tight supply with demonstrated demand. That’s basic valuation mechanics, not speculation.
Where I do draw the line is on the stocks surging purely on buyback announcements or vague “turnaround” narratives without substance. A company posting 8 billion won in quarterly revenue announcing a 2 billion won share buyback and calling it a catalyst is financial theater. The operating leverage isn’t there yet. Investors are paying for hope, not earnings. I’m also skeptical of the skin microbiome and exosome cosmetic ingredient companies bundling themselves into the biotech IPO wave — these are niche B2B ingredient suppliers, not drug developers, and the valuation frameworks being applied to them are simply wrong. The government’s growth enterprise listing exemptions have a long history of allowing pre-revenue companies to access public markets at prices that only make sense if every clinical trial succeeds. They don’t.
My approach is unchanged: ignore the sector label, interrogate the cash flows, and ask what you’re actually buying. Right now in Korean small-cap biotech, there are perhaps three genuinely interesting situations for every ten that are pure momentum plays. The challenge is having the discipline to hold that distinction when everything around you is going up.
Look, I respect the macro framework and I respect the balance sheet analysis, but right now the market is telling us something very simple, and I think we’re at risk of talking ourselves out of a real opportunity by being too clever. The small-cap and mid-cap KOSDAQ names that got absolutely destroyed over the past 18 months — we’re talking stocks down 50%, 60%, 70% from peak — are bouncing. That’s not surprising. What’s interesting is the sequence.
This isn’t random. It rhymes almost perfectly with the 2012-to-2015 period when large-cap underperformance — driven by the end of the China-fueled “Cha-Hwa-Jeong” cycle — created the conditions for a sustained small and mid-cap renaissance. We had three years where nimble domestic companies, particularly in handsets, cosmetics, and healthcare, massively outperformed the index heavyweights. The setup today is structurally similar: a handful of mega-caps are doing the heavy lifting on the index, everyone is crowded into Samsung and Hynix plays including the new 2x leveraged ETFs that are mechanically amplifying those names, and meanwhile the rest of the market is sitting at historically cheap levels with very little institutional ownership. When that rotation comes — and given the IPO calendar and the new foreign retail access, I think it’s already starting — KOSDAQ biotech is one of the first sectors to move because it has the highest beta and the most retail following.
The IPO activity is the tell. Large, high-profile listings tend to suppress secondary market activity while they’re pricing — retail money gets locked up in subscription deposits, institutions are focused on allocations. The moment those IPOs clear and refunds hit accounts, that capital re-enters the secondary market looking for the next trade. Biotech stocks with buyback announcements, CDMO companies showing order intake improvement, and anything with a credible clinical data catalyst in the next two quarters are all going to see that money. I’m not saying close your eyes and buy everything. I’m saying the rotation is real, the timing is now, and the people waiting for the perfect fundamental setup are going to be watching from the sidelines.
Synthesis: A Sector Worth Watching, With Eyes Open
The debate among our three analysts reflects a broader tension running through Korean markets right now. The macro environment — driven by AI-fueled semiconductor demand, new foreign investor access, and a historically strong bull market — is creating genuine opportunities across the KOSDAQ biotech landscape, but not indiscriminately. The smart money appears to be distinguishing between IPOs with real technological differentiation and institutional credibility, and the wave of smaller names simply surfing the momentum. For investors navigating this space, the Pragmatist’s directional read on the rotation, filtered through the Value Hunter’s balance sheet discipline and tempered by the Bear’s awareness of how quickly global macro can reverse Korean small-cap sentiment, may be the most defensible posture of all.